Ann: Quarterly Update and Appendix 4C, page-4

Some point extracted from today’s ann that should make the market (hopefully regardless diamond’s effect)) bit more confident:

1- Upon commencement of the Company’s pivotal trial of ATL1102 in Europe, Dr Price’s responsibilities will also include pharmacovigilance oversight, adverse event reporting and clinical safety monitoring
***announcing something like that in my view it looks agreement with EMA for 2b is given for granted.***

2- Following the recently reported positive clinical trial results in the Phase II clinical trial of ATL1102, the Company is actively exploring clinical development opportunities where inflammation plays a key role in disease progression.
ATL1102 was previously shown to be highly effective in reducing MS inflammatory brain lesions in a Phase IIa clinical trial in Relapsing Remitting -MS patients.
***also here management sound due to results sound very confident to explore applications ***

Now we need the much waited announcement referring DMD final report/results...